Limitations, agreements, and source contact

Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST) · Source last updated 2021-01-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

GT60

restrictive Agreement

true

limitations And Caveats

description

Overall survival results are confounded by the fact that 85% of the participants initially randomized to placebo switched to open-label regorafenib.

point Of Contact

email

clinical-trials-contact@bayer.com

organization

BAYER

title

Therapeutic Area Head

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice